Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVENE: Naltrexone/Bupropion CV Safety Study
NCT02638129Phase 4Terminated
- Sponsor
- Orexigen Therapeutics
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of naltrexone + bupropion in obesity, Overweight, sponsored by Orexigen Therapeutics. Started Jan 2016; status: terminated.
02
Drugs
naltrexone + bupropion
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT02638129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638129.